Symbols / MSLE Stock $7.61 +6.28% Satellos Bioscience Inc.

Healthcare • Biotechnology • Canada • NGM
MSLE (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: SMA 50: SMA 200:
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. Francis Gleeson B.B.A. M.B.A
Exch · Country NGM · Canada
Market Cap 158.53M
Enterprise Value 130.82M
Income -24.87M
Sales
FCF (ttm) -14.76M
Book/sh 1.80
Cash/sh 1.33
Employees 18
Insider 10d
IPO Aug 03, 2012
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E
Forward P/E -2.29
PEG
P/S
P/B 4.23
P/C
EV/EBITDA -4.95
EV/Sales
Quick Ratio 6.84
Current Ratio 7.77
Debt/Eq
LT Debt/Eq
EPS (ttm) -1.70
EPS next Y -3.33
EPS Growth
Revenue Growth
EPS Gr Q/Q
Rev Gr Q/Q
Earnings (next) 2026-05-13
Earnings (prior) 2026-03-27
ROA -40.02%
ROE -66.37%
ROIC
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 20.83M
Shs Float 19.39M
Insider Own 1.67%
Instit Own 6.15%
Short Float
Short Ratio 0.72
Short Interest 69.47K
52W High 13.39
vs 52W High -43.19%
52W Low 4.52
vs 52W Low 68.21%
Beta 1.08
Impl. Vol.
Rel Volume 0.95
Avg Volume 82.72K
Volume 78.44K
Target (mean) $30.00
Tgt Median $30.00
Tgt Low $20.00
Tgt High $40.00
# Analysts 2
Recom Strong_buy
Prev Close $7.16
Price $7.61
Change 6.28%
About

Satellos Bioscience Inc., a clinical-stage drug development company, focuses on restoring natural muscle repair and regeneration in degenerative muscle diseases in Canada, the United States, and Australia. The company uses its proprietary discovery platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo. It develops SAT-3247, an oral, small molecule drug candidate for the treatment of Duchenne muscular dystrophy disease. The company has a license agreement the with Ottawa Hospital Research Institute (OHRI); and an option agreement with the University of British Columbia. Satellos Bioscience Inc. was founded in 2018 and is headquartered in Toronto, Canada.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus Mean price target
2. Current target Latest analyst target
3. DCF / Fair value Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$7.61
Low
$20.00
High
$40.00
Mean
$30.00

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-04-28 init Guggenheim — → Buy $23
2026-04-06 init Leerink Partners — → Outperform $20
2026-03-30 main HC Wainwright & Co. Buy → Buy $11
2026-03-11 init Cantor Fitzgerald — → Overweight
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-04-07 Nawacki (Mark Henry CPA) Director of Issuer 4,500
2026-04-06 Nawacki (Mark Henry CPA) Director of Issuer 5,500
2026-02-09 Berger (Franklin Milan) Director of Issuer 24,750 $10.10 $249,975
2026-01-30 Berger (Franklin Milan) Director of Issuer 7,222,417
2026-01-30 Bloom (Brian Matthew) Director of Issuer 739,572
2026-01-30 Bloom (Brian Matthew) Director of Issuer 616,005
2026-01-30 Bloom (Brian Matthew) Director of Issuer 5,591,674
2026-01-30 Bloom (Brian Matthew) Director of Issuer 5,520,167
2026-01-30 Gleeson (Francis Michael) Director of Issuer 2,968,369
2026-01-30 Gleeson (Francis Michael) Director of Issuer 676,655
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Cost Of Revenue
Reconciled Cost Of Revenue
Gross Profit
Operating Expense
26.46
+29.71%
20.40
+75.00%
11.66
+87.70%
6.21
Research And Development
18.43
+28.32%
14.36
+116.04%
6.65
+141.57%
2.75
Selling General And Administration
7.44
+36.43%
5.45
+19.37%
4.57
+56.53%
2.92
General And Administrative Expense
7.44
+36.43%
5.45
+19.37%
4.57
+56.53%
2.92
Salaries And Wages
5.06
+34.54%
3.76
+37.90%
2.73
+56.44%
1.74
Other Gand A
2.37
+40.64%
1.69
-8.15%
1.84
+56.67%
1.17
Other Operating Expenses
0.59
+3.15%
0.57
+30.83%
0.44
+49.47%
0.29
Total Expenses
26.46
+29.71%
20.40
+75.00%
11.66
+87.70%
6.21
Operating Income
-26.46
-29.71%
-20.40
-75.00%
-11.66
-87.70%
-6.21
Total Operating Income As Reported
-19.38
-66.23%
-11.66
-87.70%
-6.21
EBITDA
-26.45
-29.78%
-20.38
-72.18%
-11.84
-46.33%
-8.09
Normalized EBITDA
-26.85
-40.26%
-19.14
-79.82%
-10.65
-79.98%
-5.92
Reconciled Depreciation
0.00
-73.33%
0.01
+184.27%
0.01
-97.87%
0.25
EBIT
-26.46
-29.71%
-20.40
-72.22%
-11.84
-42.04%
-8.34
Total Unusual Items
0.40
+132.12%
-1.24
-3.90%
-1.19
+45.17%
-2.18
Total Unusual Items Excluding Goodwill
0.40
+132.12%
-1.24
-3.90%
-1.19
+45.17%
-2.18
Special Income Charges
0.00
+100.00%
-2.90
-804.64%
-0.32
+84.89%
-2.13
Other Special Charges
0.32
Impairment Of Capital Assets
0.00
-100.00%
2.90
0.00
-100.00%
2.13
Restructuring And Mergern Acquisition
0.00
Net Income
-24.87
-20.54%
-20.63
-72.28%
-11.98
-43.57%
-8.34
Pretax Income
-24.70
-19.71%
-20.63
-72.28%
-11.98
-43.64%
-8.34
Net Non Operating Interest Income Expense
1.36
+35.59%
1.00
+15.10%
0.87
+1777.25%
0.05
Interest Expense Non Operating
0.00
-100.00%
0.13
0.00
Net Interest Income
1.36
+35.59%
1.00
+15.10%
0.87
+1777.25%
0.05
Interest Expense
0.00
-100.00%
0.13
0.00
Interest Income Non Operating
1.36
+35.59%
1.00
-0.18%
1.00
+2064.68%
0.05
Interest Income
1.36
+35.59%
1.00
-0.18%
1.00
+2064.68%
0.05
Other Income Expense
0.40
+132.12%
-1.24
-3.90%
-1.19
+45.17%
-2.18
Other Non Operating Income Expenses
-0.04
Gain On Sale Of Security
0.40
-76.11%
1.67
+291.19%
-0.87
-1665.17%
-0.05
Tax Provision
0.17
0.00
0.00
-100.00%
0.00
Tax Rate For Calcs
0.00
0.00
0.00
-100.00%
0.00
Tax Effect Of Unusual Items
0.06
0.00
0.00
+100.00%
-0.57
Net Income Including Noncontrolling Interests
-24.87
-20.54%
-20.63
-72.28%
-11.98
-43.57%
-8.34
Net Income From Continuing Operation Net Minority Interest
-24.87
-20.54%
-20.63
-72.28%
-11.98
-43.57%
-8.34
Net Income From Continuing And Discontinued Operation
-24.87
-20.54%
-20.63
-72.28%
-11.98
-43.57%
-8.34
Net Income Continuous Operations
-24.87
-20.54%
-20.63
-72.28%
-11.98
-43.57%
-8.34
Normalized Income
-25.21
-29.99%
-19.39
-79.84%
-10.78
-60.08%
-6.74
Net Income Common Stockholders
-24.87
-20.54%
-20.63
-72.28%
-11.98
-43.57%
-8.34
Diluted EPS
-20.40
-844.44%
-2.16
-32.66%
-1.63
+42.45%
-2.83
Basic EPS
-20.40
-844.44%
-2.16
-32.66%
-1.63
+42.45%
-2.83
Basic Average Shares
1.22
-87.28%
9.56
+32.84%
7.20
+142.17%
2.97
Diluted Average Shares
1.22
-87.28%
9.56
+32.84%
7.20
+142.17%
2.97
Diluted NI Availto Com Stockholders
-24.87
-20.54%
-20.63
-72.28%
-11.98
-43.57%
-8.34
Amortization
0.00
-100.00%
0.25
Amortization Of Intangibles Income Statement
0.00
-100.00%
0.25
Depreciation Amortization Depletion Income Statement
0.01
-66.67%
0.01
+184.27%
0.01
-97.87%
0.25
Depreciation And Amortization In Income Statement
0.01
-66.67%
0.01
+184.27%
0.01
-97.87%
0.25
Depreciation Income Statement
0.01
-66.67%
0.01
+184.27%
0.01
+79.04%
0.00
Insurance And Claims
0.03
Total Other Finance Cost
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
31.89
-37.16%
50.75
+51.53%
33.49
+633.23%
4.57
Current Assets
31.88
-37.17%
50.74
+66.46%
30.48
+1752.73%
1.65
Cash Cash Equivalents And Short Term Investments
27.71
-42.92%
48.55
+62.22%
29.93
+2011.07%
1.42
Cash And Cash Equivalents
9.80
-75.53%
40.07
+140.23%
16.68
+1076.69%
1.42
Cash Equivalents
5.42
-65.45%
15.69
-3.01%
16.18
+1875.96%
0.82
Cash Financial
4.38
-82.02%
24.39
+5211.85%
0.46
-23.36%
0.60
Other Short Term Investments
17.91
+111.28%
8.47
-36.02%
13.25
Receivables
0.37
-14.94%
0.43
-1.36%
0.44
+130.20%
0.19
Accounts Receivable
0.00
Taxes Receivable
0.37
-14.94%
0.43
-1.36%
0.44
+130.20%
0.19
Prepaid Assets
3.80
+116.14%
1.76
+1471.43%
0.11
+230.45%
0.03
Hedging Assets Current
0.00
0.00
-100.00%
0.00
+35.72%
0.00
Total Non Current Assets
0.01
+25.00%
0.00
-99.87%
3.01
+2.88%
2.92
Net PPE
0.01
+25.00%
0.00
-73.33%
0.01
+126.20%
0.01
Gross PPE
0.00
-75.68%
0.01
+38.84%
0.01
Accumulated Depreciation
-0.01
-252.87%
-0.00
Machinery Furniture Equipment
0.03
+210.22%
0.01
Other Properties
0.00
-75.68%
0.01
Goodwill And Other Intangible Assets
0.00
0.00
-100.00%
2.96
+2.62%
2.89
Other Intangible Assets
3.92
Investments And Advances
0.00
0.00
-100.00%
0.03
+0.17%
0.03
Other Non Current Assets
2.99
Total Liabilities Net Minority Interest
4.11
+14.57%
3.58
+31.05%
2.73
+31.12%
2.09
Current Liabilities
4.11
+14.57%
3.58
+31.05%
2.73
+31.12%
2.09
Payables And Accrued Expenses
4.11
+14.57%
3.58
+31.05%
2.73
+31.12%
2.09
Payables
1.84
-10.62%
2.06
+163.15%
0.78
-27.42%
1.08
Accounts Payable
1.77
-14.11%
2.06
+163.15%
0.78
-27.42%
1.08
Current Accrued Expenses
2.26
+48.75%
1.52
-21.96%
1.95
+93.81%
1.01
Total Tax Payable
0.07
0.00
Income Tax Payable
0.07
0.00
Total Non Current Liabilities Net Minority Interest
0.00
0.00
0.00
0.00
Stockholders Equity
27.78
-41.09%
47.16
+53.35%
30.76
+1139.00%
2.48
Common Stock Equity
27.78
-41.09%
47.16
+53.35%
30.76
+1139.00%
2.48
Capital Stock
85.83
+9.85%
78.13
+65.06%
47.34
+112.66%
22.26
Common Stock
85.83
+9.85%
78.13
+65.06%
47.34
+112.66%
22.26
Share Issued
15.46
+11.87%
13.82
+47.01%
9.40
+169.85%
3.48
Ordinary Shares Number
15.46
+11.87%
13.82
+47.01%
9.40
+169.85%
3.48
Additional Paid In Capital
10.17
+28.68%
7.90
+22.06%
6.47
+138.17%
2.72
Retained Earnings
-81.97
-43.56%
-57.10
-56.59%
-36.46
-56.54%
-23.29
Gains Losses Not Affecting Retained Earnings
-1.72
+0.98%
-1.74
-579.83%
0.36
+7118.66%
-0.01
Other Equity Adjustments
-1.72
+0.98%
-1.74
-579.83%
0.36
+7118.66%
-0.01
Total Equity Gross Minority Interest
27.78
-41.09%
47.16
+53.35%
30.76
+1139.00%
2.48
Total Capitalization
27.78
-41.09%
47.16
+53.35%
30.76
+1139.00%
2.48
Working Capital
27.78
-41.10%
47.16
+69.95%
27.75
+6408.37%
-0.44
Invested Capital
27.78
-41.09%
47.16
+53.35%
30.76
+1139.00%
2.48
Net Tangible Assets
27.78
-41.09%
47.16
+53.35%
30.76
+7731.09%
-0.40
Tangible Book Value
27.78
-41.09%
47.16
+53.35%
30.76
+7731.09%
-0.40
Other Equity Interest
15.48
-22.47%
19.97
+53.00%
13.05
+1521.93%
0.80
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-23.60
-29.28%
-18.25
-109.00%
-8.73
-104.95%
-4.26
Cash Flow From Continuing Operating Activities
-23.60
-29.28%
-18.25
-109.00%
-8.73
-110.03%
-4.16
Net Income From Continuing Operations
-24.87
-20.54%
-20.63
-72.28%
-11.98
-43.57%
-8.34
Depreciation Amortization Depletion
0.00
-73.33%
0.01
+184.27%
0.01
-97.87%
0.25
Depreciation
0.00
-73.33%
0.01
+184.27%
0.01
+79.04%
0.00
Amortization Cash Flow
0.00
-100.00%
0.25
Depreciation And Amortization
0.00
-73.33%
0.01
+184.27%
0.01
-97.87%
0.25
Amortization Of Intangibles
0.00
-100.00%
0.25
Other Non Cash Items
-0.36
-368.32%
0.13
+229.34%
-0.10
Stock Based Compensation
3.23
+97.14%
1.64
+0.37%
1.64
+54.10%
1.06
Asset Impairment Charge
0.00
-100.00%
2.90
0.00
-100.00%
2.13
Operating Gains Losses
-0.48
+54.68%
-1.07
-189.56%
1.19
+6373.96%
0.02
Gain Loss On Investment Securities
0.00
+497.98%
-0.00
+97.73%
-0.03
Net Foreign Currency Exchange Gain Loss
-0.48
+54.81%
-1.07
-222.80%
0.87
+1590.98%
0.05
Change In Working Capital
-1.48
-96.28%
-0.75
-370.71%
0.28
-61.91%
0.73
Change In Receivables
0.07
+303.13%
-0.03
+86.86%
-0.24
-223.76%
0.20
Changes In Account Receivables
0.00
Change In Prepaid Assets
-2.04
-17.95%
-1.73
-2153.92%
-0.08
-5117.64%
-0.00
Change In Payables And Accrued Expense
0.50
-50.49%
1.01
+69.08%
0.60
+11.89%
0.53
Investing Cash Flow
-9.42
-302.26%
4.66
+135.22%
-13.22
-597984.67%
-0.00
Cash Flow From Continuing Investing Activities
-9.42
-302.26%
4.66
+135.22%
-13.22
-597984.67%
-0.00
Net PPE Purchase And Sale
-0.01
-50.00%
-0.00
+70.52%
-0.01
-513.84%
-0.00
Purchase Of PPE
-0.01
-50.00%
-0.00
+70.52%
-0.01
-513.84%
-0.00
Capital Expenditure
-0.01
-50.00%
-0.00
+70.52%
-0.01
-513.84%
-0.00
Net Investment Purchase And Sale
-9.41
-301.95%
4.66
+135.29%
-13.21
0.00
Purchase Of Investment
-23.37
+14.76%
-27.42
-107.59%
-13.21
0.00
Sale Of Investment
13.96
-56.48%
32.08
0.00
Net Business Purchase And Sale
0.00
Net Other Investing Changes
Financing Cash Flow
2.24
-94.04%
37.57
-1.16%
38.01
+1759.18%
2.04
Cash Flow From Continuing Financing Activities
2.24
-94.04%
37.57
-1.50%
38.15
+1765.70%
2.04
Net Issuance Payments Of Debt
0.00
+100.00%
-0.28
0.00
Issuance Of Debt
0.00
-100.00%
1.69
0.00
Repayment Of Debt
0.00
+100.00%
-1.98
0.00
Long Term Debt Issuance
0.00
-100.00%
1.69
0.00
Long Term Debt Payments
0.00
+100.00%
-1.98
0.00
Net Long Term Debt Issuance
0.00
+100.00%
-0.28
0.00
Net Common Stock Issuance
0.00
-100.00%
30.06
+22.83%
24.47
+1096.82%
2.04
Cash Dividends Paid
0.00
0.00
Proceeds From Stock Option Exercised
2.24
-70.19%
7.52
-45.64%
13.83
0.00
Net Other Financing Charges
0.45
Changes In Cash
-30.77
-228.33%
23.98
+49.30%
16.06
+859.23%
-2.12
Effect Of Exchange Rate Changes
0.50
+185.84%
-0.59
+33.16%
-0.88
-1465.56%
-0.06
Beginning Cash Position
40.07
+140.23%
16.68
+1050.16%
1.45
-59.59%
3.59
End Cash Position
9.80
-75.53%
40.07
+140.91%
16.63
+1073.39%
1.42
Free Cash Flow
-23.60
-29.28%
-18.26
-108.73%
-8.75
-105.16%
-4.26
Common Stock Issuance
0.00
-100.00%
30.06
+22.83%
24.47
+1096.82%
2.04
Interest Paid CFF
-0.07
0.00
Issuance Of Capital Stock
0.00
-100.00%
30.06
+22.83%
24.47
+1096.82%
2.04
Sale Of Business
0.00
SEC Filings

No SEC filings found for this symbol (may be non-US or ticker not in SEC index).

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category